pCONus Treatment of Wide Neck Intracranial Aneurysms
- Conditions
- Intracranial Aneurysm
- Registration Number
- NCT02554708
- Lead Sponsor
- Phenox GmbH
- Brief Summary
To assess safety and efficacy of pCONus for the treatment of wide neck bifurcation aneurysms.
- Detailed Description
Title: pCONus Treatment of Wide Neck Intracranial Aneurysms
Acronym: pToWin
Device: pCONus Bifurcation Aneurysm Implant
Study design: Prospective, multicenter, single-arm clinical investigation
Purpose: To assess safety and efficacy of pCONus for the treatment of wide neck bifurcation aneurysms
Duration of the study: 48 months
Sample size: 100 evaluable patients
Number of sites: \> 20
Follow-up intervals: Two independent follow-ups (after 3-6 and 7-12 months) according to site specific standard
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 116
-
Aneurysm status:
- Unruptured aneurysm or
- Ruptured aneurysm with a Hunt and Hess grade of I - III.
-
Age ≥18 and ≤ 80 years.
-
The patient or legal representative provides written informed consent.
-
The patient shows general compliance to follow the medical regimen and to attend follow-up examinations.
-
The target aneurysm is located at one of the following cerebral vessel bifurcations: ICA terminus, AcomA, MCA or BA.
-
Bifurcation wide neck aneurysm.
-
The dome height should allow for safe deployment of the device crown. The fundus of the aneurysm should offer enough space for the crown of the pCONus to deploy.
-
Vessel tortuosity precluding safe access and device deployment.
-
Stenosis within the vascular access or target vessel ≥ 50 %.
-
The target aneurysm has been previously treated with a stent or an intraaneurysmal implant beside coils.
-
The treatment plan for the target aneurysm includes the use of additional intra- and/or extraaneurysmal temporary or permanent implants other than coils.
-
More than one intracerebral aneurysm requires the treatment within the following 6 months.
-
Imaging evidence of an arteriovenous cerebrovascular malformation or a dural fistula.
-
Any physical, medical or psychiatric condition of the patient interfering with the adherence of the requirements and follow-up regimen of the study.
-
Any neurological disorder with progressive neurological symptoms, except attributable to a compressive effect of the target aneurysm.
-
Current involvement in another study or trial.
-
Women of child bearing potential or breast-feeding who cannot provide a negative pregnancy test.
-
Known allergy to the components of device, study medication or contrast media that cannot be controlled medically.
-
A medical condition interfering with a dual antiplatelet treatment.
-
Known coagulopathy.
-
Intracranial hemorrhage in the past 30 days apart from the target aneurysm.
-
Ischemic stroke in the past 30 days.
-
Myocardial infarction in the past 30 days.
-
Major surgery in the past 30 days.
-
Evidence of active infection at time of treatment.
-
Co -morbidities or conditions with a life expectancy less than 12 months.
-
Additional Exclusion criteria for ruptured aneurysm at the acute phase:
- The patient is clinically severely affected (Hunt and Hess grade IV and V).
- Severe vasospasm is proven during angiography.
- Proven parenchymal hemorrhage by CT or MRI.
- Proven subdural hematoma by CT or MRI.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness Aneurysm occlusion (complete or neck remnant) Change from post-procedure to 3-6 and to 7-12 months Safety Major stroke (ischemic or hemorrhagic) or neurological death related to the treatment of the target aneurysm within 12 months
- Secondary Outcome Measures
Name Time Method Safety Intra-Procedural Complications at the time of the procedure The "Safety Intra-Procedural Complications" endpoint is assessed throughout the intervention and is assessed as "number/amount of" for each following point:
* Vessel perforation
* Target aneurysm perforation with microcatheter or guidewire
* Target aneurysm perforation with pCONus
* Target aneurysm perforation with coils
* Thromboembolism
* Dissection of any access vesselSafety Post-Procedural Complications Change 1day post procedure up to 12months The "Safety Post-Procedural Complications" endpoint is assessed throughout the intervention and is assessed as "number/amount of" for each following point:
* Frequency of new parenchymal hemorrhage during the follow-up period
* Frequency of new subarachnoid hemorrhage during the follow-up period
* Frequency of new ischemic stroke on follow-up imaging
* Rupture of the target aneurysm during the 12 months follow-up period
* Rate of in-stent-stenosis
* Rate of in-stent-thrombosisEffectiveness at the time of the procedure The "Effectiveness endpoint" is assessed throughout the intervention and is assessed as "number/amount of" for each following point:
* To place pCONus in the desired location
* Correct opening of the device (crown and shaft)
* To perform aneurysm occlusion without obliteration of side branches and
* To detach the device at the end of the procedure
Trial Locations
- Locations (10)
Klinikum Stuttgart Katharinenhospital
🇩🇪Stuttgart, Germany
LKH-Univ. Klinikum Graz Universitätsklinik für Radiologie
🇦🇹Graz, Austria
Hôpital Pierre Wertheimer (HCL Groupement Hospitalier Est)
🇫🇷Bron cedex, France
KRH Klinikum Nordstadt
🇩🇪Hannover, Niedersachsen, Germany
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Gemeinschaftsklinikum Mittelrhein gGmbH
🇩🇪Koblenz, Germany
Klinikum Osnabrück
🇩🇪Osnabrück, Germany
Knappschaftskrankenhaus Recklinghausen
🇩🇪Recklinghausen, Germany
A.S.L. Napoli 1 Centro - P.O. San Giovanni Bosco
🇮🇹Napoli, Italy
Clínica La Sagrada Familia Department of Neuroscience (P.L.), Equipo de Neurocirugía Endovascular y Radiología Intervencionista
🇦🇷Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina